AR099529A1 - Derivados de etinilo, un proceso para su fabricación; composiciones farmacéuticas que los comprenden y su uso en el tratamiento de enfermedades del sistema nervioso o cáncer - Google Patents
Derivados de etinilo, un proceso para su fabricación; composiciones farmacéuticas que los comprenden y su uso en el tratamiento de enfermedades del sistema nervioso o cáncerInfo
- Publication number
- AR099529A1 AR099529A1 ARP150100537A ARP150100537A AR099529A1 AR 099529 A1 AR099529 A1 AR 099529A1 AR P150100537 A ARP150100537 A AR P150100537A AR P150100537 A ARP150100537 A AR P150100537A AR 099529 A1 AR099529 A1 AR 099529A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- hydrogen
- halogen
- optionally substituted
- pyridinyl
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002431 hydrogen Chemical group 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000004076 pyridyl group Chemical group 0.000 abstract 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- -1 1-methylpyrrolo [2,3-b] pyridin-5-yl Chemical group 0.000 abstract 1
- 125000001963 4 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000004942 pyridazin-6-yl group Chemical group N1=NC=CC=C1* 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Compuestos de fórmula (1) en el que Y es N o C-R¹; R¹ es hidrógeno o F; R¹ es hidrógeno, halógeno o alquilo inferior sustituido con halógeno; R² es hidrógeno o alquilo inferior; o R² forma junto con R⁴ un anillo heterocíclico de 6 miembros que contiene -CH₂-CH₂-O-CH₂ o -CH₂-CH₂-NR-C(O)-; R es hidrógeno, alquilo inferior, fenilo o bencilo; R³ es fenilo o piridinilo, en el que el átomo de N en cl grupo de piridinilo puede estar en diferentes posiciones; R⁴ es hidrógeno, alquilo inferior o alcoxialquilo inferior; R⁴ es hidrógeno, alquilo inferior, fenilo opcionalmente sustituido con halógeno o alcoxi inferior, o es cicloalquilo, o es piridinilo opcionalmente sustituido con halógeno, alquilo inferior, alcoxi inferior o =O, o es pirimidinilo opcionalmente sustituido con alquilo inferior, alcoxi inferior o =O, o es 1-alquilo inferior-piridinilo, o es pirazinilo, o es piridazinilo opcionalmente sustituido con alquilo inferior, alcoxi inferior o =O, o es 1-metilpirrolo[2,3-b]piridin-5-il, o es 6-imidazo[1,2-b]piridazin-6-il; o R⁴ forma junto con R⁴ un anillo heterocíclico de 4, 5 ó 6 miembros que contiene -(CH₂)₅-, -CH₂-CH₂-O-CH₂-CH₂-, -CH₂-CH₂-CH₂-, -CH₂-CH₂-CH₂-CH₂-, -CH₂-O-CH₂-CH₂- o CH₂-CH₂-CH₂-O-CH₂; R⁵ y R⁵ son hidrógeno o alquilo inferior; o R⁴ forma junto con R⁵ un anillo saturado de 5 miembros que contiene -CH₂-CH₂-CH₂-; o a una sal farmacéuticamente aceptable o sal de adición de ácido, a una mezcla racémica, o a su correspondiente enantiómero y/o isómero óptico y/o estereoisómeros del mismo. Los compuestos pueden usarse en el tratamiento de la enfermedad de Parkinson, ansiedad, emesis, trastorno obsesivo-compulsivo, autismo, neuroprotección, cáncer, depresión y diabetes de tipo 2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14156461 | 2014-02-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099529A1 true AR099529A1 (es) | 2016-07-27 |
Family
ID=50151209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150100537A AR099529A1 (es) | 2014-02-25 | 2015-02-24 | Derivados de etinilo, un proceso para su fabricación; composiciones farmacéuticas que los comprenden y su uso en el tratamiento de enfermedades del sistema nervioso o cáncer |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US9725416B2 (es) |
| EP (1) | EP3110802B1 (es) |
| JP (1) | JP6286577B2 (es) |
| KR (1) | KR101792452B1 (es) |
| CN (1) | CN106029649B (es) |
| AR (1) | AR099529A1 (es) |
| AU (1) | AU2015222303B2 (es) |
| BR (1) | BR112016017816A8 (es) |
| CA (1) | CA2938009A1 (es) |
| CL (1) | CL2016002064A1 (es) |
| CR (1) | CR20160384A (es) |
| DK (1) | DK3110802T3 (es) |
| EA (1) | EA029261B1 (es) |
| ES (1) | ES2701167T3 (es) |
| HR (1) | HRP20182016T1 (es) |
| HU (1) | HUE041392T2 (es) |
| IL (1) | IL246842B (es) |
| LT (1) | LT3110802T (es) |
| MA (1) | MA39305A3 (es) |
| MX (1) | MX369819B (es) |
| PE (1) | PE20161415A1 (es) |
| PH (1) | PH12016501481B1 (es) |
| PL (1) | PL3110802T3 (es) |
| PT (1) | PT3110802T (es) |
| RS (1) | RS58208B1 (es) |
| SG (1) | SG11201607010XA (es) |
| SI (1) | SI3110802T1 (es) |
| TW (1) | TWI576340B (es) |
| UA (1) | UA117855C2 (es) |
| WO (1) | WO2015128307A1 (es) |
| ZA (1) | ZA201605243B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107207481B (zh) * | 2015-03-19 | 2020-03-03 | 豪夫迈·罗氏有限公司 | 作为mglur4的调节剂的3-(4-乙炔基苯基)六氢嘧啶-2,4-二酮衍生物 |
| AU2016273751B2 (en) | 2015-06-03 | 2020-04-02 | F. Hoffmann-La Roche Ag | Ethynyl derivatives |
| MA42442B1 (fr) | 2015-07-15 | 2019-07-31 | Hoffmann La Roche | Dérivés d'éthynyle comme modulateurs du récepteur métabotropique au glutamate |
| AR105556A1 (es) * | 2015-08-03 | 2017-10-18 | Hoffmann La Roche | Derivados de etinilo |
| CA3030788A1 (en) | 2016-07-18 | 2018-01-25 | F. Hoffmann-La Roche Ag | Ethynyl derivatives |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012004919A2 (pt) * | 2009-09-04 | 2019-09-24 | Univ Vanderbilt | potencializadores alostericos de mglur4, composição e metodos de tratamentos de disfunção neurologica |
| US8759377B2 (en) * | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| PL3049409T3 (pl) * | 2013-09-25 | 2017-09-29 | F.Hoffmann-La Roche Ag | Pochodne etynylowe |
| TWI649310B (zh) * | 2014-01-10 | 2019-02-01 | 赫孚孟拉羅股份公司 | 乙炔基衍生物 |
-
2015
- 2015-02-24 EA EA201691690A patent/EA029261B1/ru not_active IP Right Cessation
- 2015-02-24 KR KR1020167023095A patent/KR101792452B1/ko not_active Expired - Fee Related
- 2015-02-24 UA UAA201609882A patent/UA117855C2/uk unknown
- 2015-02-24 ES ES15706788T patent/ES2701167T3/es active Active
- 2015-02-24 JP JP2016554209A patent/JP6286577B2/ja not_active Expired - Fee Related
- 2015-02-24 PT PT15706788T patent/PT3110802T/pt unknown
- 2015-02-24 RS RS20181482A patent/RS58208B1/sr unknown
- 2015-02-24 DK DK15706788.5T patent/DK3110802T3/en active
- 2015-02-24 AR ARP150100537A patent/AR099529A1/es unknown
- 2015-02-24 LT LTEP15706788.5T patent/LT3110802T/lt unknown
- 2015-02-24 EP EP15706788.5A patent/EP3110802B1/en active Active
- 2015-02-24 MX MX2016011099A patent/MX369819B/es active IP Right Grant
- 2015-02-24 AU AU2015222303A patent/AU2015222303B2/en not_active Ceased
- 2015-02-24 WO PCT/EP2015/053785 patent/WO2015128307A1/en not_active Ceased
- 2015-02-24 TW TW104105911A patent/TWI576340B/zh not_active IP Right Cessation
- 2015-02-24 HU HUE15706788A patent/HUE041392T2/hu unknown
- 2015-02-24 PL PL15706788T patent/PL3110802T3/pl unknown
- 2015-02-24 CR CR20160384A patent/CR20160384A/es unknown
- 2015-02-24 BR BR112016017816A patent/BR112016017816A8/pt not_active Application Discontinuation
- 2015-02-24 CN CN201580010032.2A patent/CN106029649B/zh not_active Expired - Fee Related
- 2015-02-24 SG SG11201607010XA patent/SG11201607010XA/en unknown
- 2015-02-24 PE PE2016001503A patent/PE20161415A1/es unknown
- 2015-02-24 MA MA39305A patent/MA39305A3/fr unknown
- 2015-02-24 SI SI201530503T patent/SI3110802T1/sl unknown
- 2015-02-24 HR HRP20182016TT patent/HRP20182016T1/hr unknown
- 2015-02-24 CA CA2938009A patent/CA2938009A1/en not_active Abandoned
-
2016
- 2016-07-19 IL IL246842A patent/IL246842B/en active IP Right Grant
- 2016-07-27 PH PH12016501481A patent/PH12016501481B1/en unknown
- 2016-07-28 ZA ZA2016/05243A patent/ZA201605243B/en unknown
- 2016-08-16 CL CL2016002064A patent/CL2016002064A1/es unknown
- 2016-08-24 US US15/245,955 patent/US9725416B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR121661A2 (es) | Esteroides neuroactivos, composiciones y usos de los mismos | |
| ECSP19047936A (es) | Imidazopirrolopiridina como inhibidores de la familia de quinasas jak | |
| NI201900060A (es) | Inhibidores de moléculas pequeñas de la familia de quinasa jak | |
| AR095885A1 (es) | Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2 | |
| CL2018000036A1 (es) | Derivados etinilo | |
| PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
| AR101174A1 (es) | Imidazopirazinas como inhibidores de lsd1 | |
| AR099529A1 (es) | Derivados de etinilo, un proceso para su fabricación; composiciones farmacéuticas que los comprenden y su uso en el tratamiento de enfermedades del sistema nervioso o cáncer | |
| AR091781A1 (es) | Antagonistas del receptor de 5-ht3 | |
| PE20170295A1 (es) | Compuestos de imidazopiridazina | |
| PE20141553A1 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a | |
| PE20150943A1 (es) | 2-oxo-2,3-dihidro-indoles para el tratamiento de desordenes de cns | |
| AR099047A1 (es) | Derivados etinilo | |
| PE20211246A1 (es) | Compuestos biciclicos para su uso como inhibidores de rip1 quinasa | |
| AR097721A1 (es) | Derivados de etinilo | |
| AR105662A1 (es) | Derivados de piridina y de pirimidina como inhibidores del eaat3 | |
| AR104863A1 (es) | Derivados imidazol | |
| PE20190778A1 (es) | Derivados de eter ciclico de pirazolo[1,5-a]pirimidin-3-carboxiamida | |
| AR103952A1 (es) | Derivados de pirimidina-diona | |
| AR105327A1 (es) | Derivados de imidazol | |
| EA201692404A1 (ru) | Пептиды, выполняющие роль агонистов окситоцина | |
| CO2018013824A2 (es) | Derivados de etinilo | |
| MX2016014845A (es) | Derivados indolin-2-ona y 1,3-dihidro-pirrol[3,2-c]piridin-2-ona. | |
| AR079842A1 (es) | Derivados de pirrolopiridina benzoico, composicion farmaceutica que los comprende y su utilizacion en la fabricacion de un medicamento para el tratamiento de las enfermedades neurodegenerativas | |
| AR081384A1 (es) | N- fenil espirolactama bipirrolidinas sustituidas, preparacion y uso terapeutico de las mismas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |